Revenues soar for NPE Acacia

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Revenues soar for NPE Acacia

Acacia Research (ACTG) reported record revenues this week of $250.7 million , up from $184.7 million the previous year

The non-practising entity (NPE) also reported record fourth quarter revenues of $66.2 million, up from $20.7 million fourth quarter last year.

Acacia held 1,238 patent publications as of January 2013, according to patent troll tracking website Patent Freedom, which ranks it ninth out of 680 NPEs polled. Acacia has engaged in litigation against high profile companies including Apple, AT&T, Sprint and Verizon.

During the fiscal year of 2012, Acacia said it acquired control of a record 55 patent portfolios.

According to its website, Acacia’s subsidiaries team up with inventors and patent owners, license the patents to corporate users, and share the revenue.

“These results reflect Acacia’s growing industry leadership in patent licensing and are accelerating new opportunities to partner with patent owners,” said the company’s CEO, Paul Ryan.

more from across site and SHARED ros bottom lb

More from across our site

New platform, which covers SEPs covering the Wi-Fi 6 and Wi-Fi 7 standards, includes 10 patent owners
The Texas-based IP litigation hires take King & Spalding’s partner appointments from pre-merger Winston & Strawn up to 12 this year
Sunny Su explains how her team overcame challenges with orchard evidence collection to secure a favourable plant variety decision from China’s top court
Flexible working firm continues trajectory from 2025 with appointment of Matthew Grant and Letao Qin
Anousha Davies, associate and trademark attorney at Birketts, unpicks how the university’s reputation enabled it to see off a proposed trademark for ‘Cambridge Rowing’
IP lawyers, who say they are encouraging clients to build up ‘tariff resilience’, should treat the risks posed by recent orders as a core consideration in cross-border licensing
Regulatory changes and damages risks are prompting Canadian firms and clients to opt for settlements in generic and biosimilar cases
News of Via Licensing Alliance adding two new members and Nokia’s proposal to extend interim licences to Warner Bros Discovery and Paramount were also among the top talking points
A new claim filed by Ericsson, and a request for access to documents, were also among recent developments
Cooley and Stikeman Elliott advised 35Pharma on the deal, which will allow GSK to get its hands on S235, an investigational medicine for pulmonary hypertension
Gift this article